

Clinical Reference Guide

ReEssence™

Centella Asiatica extract (leaf)

A. Connective tissue and tissue repair

1. Bossé JP, Papillon J, Frenette G, et al. Clinical study of a new antikeloid drug. *Ann Plastic Surg* 1979;3:13–21.
2. Kartnig T. Clinical applications of *Centella asiatica* (L) Urb. In *Herbs, Spices, and Medicinal Plants: Recent Advances in Botany, Horticulture, and Pharmacology*, vol. 3., Craker LE, Simon JE (eds). Phoenix, AZ: Oryx Press, 1986, 145–73.
3. Maquart FX, Chastang F, Simeon A, Birembaut P, Gillery P, Wegrowski Y. Triterpenes from *Centella asiatica* stimulate extracellular matrix accumulation in rat experimental wounds. *Eur J Dermatol.* 1999 Jun;9(4):289-96. *Phytother Res* 1999 Feb;13(1):50-4.
4. Maquart FX, et al. Stimulation of Collagen Synthesis in Fibroblast Cultures by a Triterpene Extracted from *Centella asiatica*. *Connect Tissue Res.* 1990;24(2):107-20.
5. Morisset R, Cote NG, Panisset JC, et al. Evaluation of the healing activity of hydrocotyle tincture in the treatment of wounds. *Phytother Res* 1987;1:117–21.
6. Poizot A, et al. Modification of the Kinetics of Healing after Iterative Exeresis in the Rat. Action of a Triterpenoid and Its Derivatives on the Duration of Healing. *C R Acad Sci Hebd Seances Acad Sci D.* 1978;286(10):789-92.
7. Rosen H, Blumenthal A, McCallum J. Effect of Asiaticoside on Wound Healing in the Rat. *Proc Soc Exp Biol Med.* May1967;125(1):279-80.
8. Shukla A; Rasik AM; Jain GK; Shankar R; Kulshrestha DK; Dhawan BN. In vitro and in vivo wound healing activity of asiaticoside isolated from *Centella asiatica*. *J Ethnopharmacol* 1999 Apr;65(1):1-11.
9. Suguna L, Sivakumar P, Chandrakasan G. Effects of *Centella asiatica* extract on dermal wound healing in rats. *Indian J Exp Biol.* 1996 Dec;34(12):1208-11.
10. Tenni R, Zanaboni G, De Agostini MP, Rossi A, Bendotti C, Cetta G. Effect of the triterpenoid fraction of *Centella asiatica* on macromolecules of the connective matrix in human skin fibroblast cultures. *Ital J Biochem.* 1988 Mar-Apr;37(2):69-77.
11. Widgerow AD, Chait LA, Stals R, Stals PJ. New innovations in scar management. *Aesthetic Plast Surg.* 2000 May-Jun;24(3):227-34.

B. Fluid balance, microcirculation and vein structure and function.

1. Allegra C. Comparative Capillaroscopic Study of Certain Bioflavonoids and Total Triterpenic Fractions of *Centella asiatica* in Venous Insufficiency. *Clin Ter.* 1981;99:507-13.
2. Belcaro GV, Grimaldi R, Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. *Angiology.* 1990 Jul;41(7):533-40.
3. Brinkhaus B, Linder M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medical plant *Centella asiatica*. *Phytomed* 2000;7:427-48.
4. Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Grimaldi R, Marelli C, Belcaro G. The microcirculatory activity of *Centella asiatica* in venous insufficiency. A double-blind study. *Minerva Cardioangiol.* 1994 Jun;42(6):299-304.
5. Cesarone MR, Laurora G, De Sanctis MT, et al. Activity of *Centella asiatica* in Venous Insufficiency. *Minerva Cardioangiol.* 1992 Apr;40(4):137-43.
6. De Sanctis MT, Incandela L, Cesarone MR, et al. Acute Effects of TTFCA on Capillary Filtration in Severe Venous Hypertension. *Panminerva Med.* Jun1994;36(2):87-90.
7. Pointel JP, Boccalon H, Cloarec M, et al. Titrated extract of *Centella asiatica* (TECA) in the treatment of venous insufficiency of the lower limbs. *Angiology* 1986;37:420-1.

C. Antioxidant activity

1. Shukla A, Rasik AM, Dhawan BN. Asiaticoside-induced Elevation of Antioxidant Levels in Healing Wounds. *Phytother Res.* Feb1999;13(1):50-4.

Butchers Broom extract (root)

A. Chronic venous insufficiency – blood vessel integrity and fluid balance

1. Cluzan RV, Alliot F, Ghabboun S, et al. Treatment of secondary lymphedema of the upper limb with CYCLO 3 FORT. *Lymphology.* 1996;29:29-35.
2. Lucker P, Jost V, Wolna P, et al. Efficacy and safety of ruscus extract compared to placebo in patients suffering from chronic venous insufficiency [abstract]. *Phytomedicine.* 2000;7(suppl 2):P-155.

3. Rudofsky G, Diehm C, Gruss JD, et al. Chronic venous insufficiency. Treatment with Ruscus extract and trimethylhesperidin chalcone [in German; English abstract]. *MMW Munch Med Wochenschr.* 1990;132:205–210.
4. Weindorf N, Schultz-Ehrenburg U. Controlled study of increasing venous tone in primary varicose veins by oral administration of Ruscus aculeatus and trimethylhesperidin chalcone [in German; English abstract]. *Z Hautkr.* 1987;62:28–30,35–38.
5. Vanscheidt W, Jost V, Wolna P, et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. *Arzneimittelforschung.* 2002;52(4):243-250.

Green Tea extract (leaf)

A. Antioxidant activity

1. Anderson JW, Diwadkar VA, Bridges SR. Selective effects of different antioxidants on oxidation of lipoproteins from rats. *Proc Soc Exp Biol Med.* 1998 Sep;218(4):376-81.
2. Benzie IF, Szeto YT, Strain JJ, Tomlinson B. Consumption of green tea causes rapid increase in plasma antioxidant power in humans. *Nutr Cancer.* 1999;34(1):83-7.
3. Benzie IF, Szeto YT. Total Antioxidant Capacity of Teas by the Ferric Reducing/Antioxidant Power Assay. *J Agric Food Chem.* Feb1999;47(2):633-6.
4. Cheng TO. Antioxidants in Chinese Green Tea. *J Am Coll Cardiol.* Apr 1998;31(5):1214.
5. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a Green Tea Extract Rich in Catechin Polyphenols and Caffeine in Increasing 24-h Energy Expenditure and Fat Oxidation in Humans. *Am J Clin Nutr.* Dec1999;70(6):1040-5.
6. Grinberg LN, et al. Protective Effects of Tea Polyphenols against Oxidative Damage to Red Blood Cells. *Biochem Pharmacol.* Nov1997;54(9):973-78.
7. Hakim IA, Harris RB, Brown S, et al. Effect of Increased Tea Consumption on Oxidative DNA Damage among Smokers: A Randomized Controlled Study. *J Nutr.* Oct2003;133(10):3303S-9S.
8. Hasegawa R, Chujo T, Sai-Kato K, Umemura T, Tanimura A, Kurokawa Y. Preventive effects of green tea against liver oxidative DNA damage and hepatotoxicity in rats treated with 2-nitropropane. *Food Chem Toxicol.* 1995 Nov;33(11):961-70.

9. Ichihashi M, Ahmed NU, Budiyo A, et al. Preventive Effect of Antioxidant on Ultraviolet-induced Skin Cancer in Mice. *J Dermatol Sci*. Mar 2000;23(Suppl 1):S45-50.
10. Katiyar SK, Afaq F, Perez A, et al. Green Tea Polyphenol (-)-Epigallocatechin-3-gallate Treatment of Human Skin inhibits Ultraviolet Radiation-induced Oxidative Stress. *Carcinogenesis*. Feb2001;22(2):287-294.
11. Katiyar SK, et al. Tea Antioxidants in Cancer Chemoprevention. *J Cell Biochem*. 1997;27(Suppl):59-67.
12. Klaunig JE, Xu Y, Han C, et al. The Effect of Tea Consumption on Oxidative Stress in Smokers and Nonsmokers. *Proc Soc Exp Biol Med*. Apr1999;220(4):249-54.
13. Kumamoto M, et al. Evaluation of the Antioxidative Activity of Tea by an Oxygen Electrode Method. *Biosci Biotechnol Biochem*. Jan1998;62(1):175-77.
14. Langley-Evans SC. Antioxidant Potential of Green and Black Tea Determined Using the Ferric Reducing Power (FRAP) Assay. *Int J Food Sci Nutr*. May2000;51(3):181-8.
15. Lee IP, Kim YH, Kang MH, et al. Chemopreventive Effect of Green Tea (*Camellia sinensis*) Against Cigarette Smoke-induced Mutations (SCE) in Humans. *J Cell Biochem Suppl*. 1997;27:68-75.
16. Leenen R, Roodenburg AJ, Tijburg LB, et al. A Single Dose of Tea With or Without Milk Increases Plasma Antioxidant Activity in Humans. *Eur J Clin Nutr*. Jan2000;54(1):87-92.
17. Lin AM, Chyi BY, Wu LY, et al. The Antioxidative Property of Green Tea Against Iron-induced Oxidative Stress in Rat Brain. *Chin J Physiol*.
18. Liu Z, Ma LP, Zhou B, et al. Antioxidative Effects of Green Tea Polyphenols on Free Radical Initiated and Photosensitized Peroxidation of Human Low Density Lipoprotein. *Chem Phys Lipids*. Jun2000;106(1):53-63.
19. Mitscher LA, et al. Chemoprotection: A Review of the Potential Therapeutic Antioxidant Properties of Green Tea (*Camellia sinensis*) and Certain of Its Constituents. *Med Res Rev*. Jul1997;17(4):327-65.
20. Satoh K, Sakagami H. Ascorbyl radical scavenging activity of polyphenols. *Anticancer Res*. 1996 Sep-Oct;16(5A):2885-90.
21. Serafini M, Ghiselli A, Ferro-Luzzi A. In vivo antioxidant effect of green tea in man. *Eur J Clin Nutr* 1996;50:28-32.

22. Sung H, Nah J, Chun S, et al. In Vivo Antioxidant Effect of Green Tea. *Eur J Clin Nutr.* Jul2000;54(7):527-9.
23. Valcic S, Burr JA, Timmermann BN, et al. Antioxidant Chemistry of Green Tea Catechins. New Oxidation Products of (-)-Epigallocatechin Gallate and (-)-Epigallocatechin from Their Reactions with Peroxyl Radicals. *Chem Res Toxicol.* Apr1999;12(4):382-6.
24. Xu Y, Ho CT, Amin SG, Han C, Chung FL. Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. *Cancer Res.* 1992 Jul 15;52(14):3875-9.
25. Zhao JF, Zhang YJ, Jin XH, et al. Green Tea Protects Against Psoralen Plus Ultraviolet A-induced Photochemical Damage to Skin. *J Invest Dermatol.* Dec1999;113(6):1070-5.
26. Zhu QY, Huang Y, Tsang D, et al. Regeneration of Alpha-tocopherol in Human Low-density Lipoprotein by Green Tea Catechin. *J Agric Food Chem.* May 1999;47(5):2020-5.

B. Fat metabolism

1. Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, Chantre P, Vandermander J. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. *Am J Clin Nutr.* 1999 Dec;70(6):1040-5.
2. Dulloo AG, Seydoux J, Girardier L, Chantre P, Vandermander J. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. *Int J Obes Relat Metab Disord.* 2000 Feb;24(2):252-8.
3. Sayama K, Lin S, Zheng G, Oguni I. Effects of green tea on growth, food utilization and lipid metabolism in mice. *In Vivo.* 2000 Jul-Aug;14(4):481-4.

C. Cardiovascular function

1. Hertog MG, et al. Antioxidant Flavonols and Ischemic Heart Disease in a Welsh Population of Men: The Caerphilly Study. *Am J Clin Nutr.* May1997;65(5):1489-94.
2. Imai K, Nakachi K. Cross Sectional Study of Effects of Drinking Green Tea on Cardiovascular and Liver Diseases. *BMJ.* Mar1995;310(6981):693-96.
3. Kono S, Shinchu K, Ikeda N, et al. Green tea consumption and serum lipid profiles: A cross-sectional study in Northern Kyushu, Japan. *Prev Med* 1992;21:526-31.

4. Miura Y, Chiba T, Miura S, et al. Green Tea Polyphenols (Flavan 3-ols) Prevent Oxidative Modification of Low Density Lipoproteins: An Ex Vivo Study in Humans. *J Nutr Biochem*. Apr2000;11(4):216-222.
5. Muramatsu K, Fukuyo M, Hara Y. Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. *J Nutr Sci Vitaminol (Tokyo)*. 1986 Dec;32(6):613-22.
6. Nakagawa K, Ninomiya M, Okubo T, et al. Tea Catechin Supplementation Increases Antioxidant Capacity and Prevents Phospholipid Hydroperoxidation in Plasma of Humans. *J Agric Food Chem*. Oct1999;47(10):3967-73.
7. Princen HM, et al. No Effect of Consumption of Green and Black Tea on Plasma Lipid and Antioxidant Levels and on LDL Oxidation in Smokers. *Arterioscler Thromb Vasc Biol*. May1998;18(5):833-41.
8. Sagesaka-Mitane Y, et al. Platelet Aggregation Inhibitors in Hot Water Extract of Green Tea. *Chem Pharm Bull. (Tokyo)*. Mar1990;38(3):790-93.
9. Sasazuki S, Komdama H, Yoshimasu K, et al. Relation between green tea consumption and severity of coronary atherosclerosis among Japanese men and women. *Ann Epidemiol* 2000;10:401-8.
10. Stensvold I, Tverdal A, Solvoll K, et al. Tea consumption. Relationship to cholesterol, blood pressure, and coronary and total mortality. *Prev Med* 1992;21:546-53.
11. Tsubono Y, Tsugane S. Green tea intake in relation to serum lipid levels in middle-aged Japanese men and women. *Ann Epidemiol* 1997;7:280-4.
12. Van het Hof KH, Wiseman SA, Yang CS, et al. Plasma and Lipoprotein Levels of Tea Catechins Following Repeated Tea Consumption. *Proc Soc Exp Biol Med*. Apr1999;220(4):203-9.
13. Yamaguchi Y, Hayashi M, Yamazoe H, et al. Preventive effects of green tea extract on lipid abnormalities in serum, liver and aorta of mice fed an atherogenic diet. *Nip Yak Zas* 1991;97:329-37.
14. Yang TT, Koo MW. Chinese green tea lowers cholesterol level through an increase in fecal lipid excretion. *Life Sci*. 2000;66(5):411-23.
15. Yang TT, Koo MW. Hypocholesterolemic effects of Chinese tea. *Pharmacol Res*. 1997 Jun;35(6):505-12.
16. Yokozawa T, et al. Influence of Green Tea and Its Three Major Components upon Low-density Lipoprotein Oxidation. *Exp Toxicol Pathol*. Dec1997;49(5):329-35.

D. Abnormal cell growth, apoptosis and antioxidant activity

1. Agarwal R, et al. Cancer Chemoprevention by Polyphenols in Green Tea and Artichoke. *Adv Exp Med Biol.* 1996;401:35-50.
2. Bushman JL. Green Tea and Cancer in Humans: A Review of the Literature. *Nutr Cancer.* 1998;31(3):151-9.
3. Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. *Prev Med* 1997;26:769–75.
4. Jankun J, et al. Why Drinking Green Tea Could Prevent Cancer. *Nature.* Jun1997;387(6633):561.
5. Jian L. Protective effect of green tea against prostate cancer: a case-control study in southeast China. *Int J Cancer.* 2004 Jan 1;108(1):130-5.
6. Katiyar SK, Mukhtar H. Tea consumption and cancer. *World Rev Nutr Diet* 1996;79:154–84 [review].
7. Kemberling JK, Hampton JA, Keck RW, Gomez MA, Selman SH. Inhibition of Bladder Tumor Growth by the Green Tea Derivative Epigallocatechin-3-Gallate. *J Urol.* Sep2003;170(3):773-776.
8. Kohlmeier L, Weterings KG, Steck S, Kok FJ. Tea and cancer prevention: an evaluation of the epidemiologic literature. *Nutr Cancer* 1997;27:1–13 [review].
9. Komori A, et al. Anticarcinogenic Activity of Green Tea Polyphenols. *Jpn J Clin Oncol.* Jun1993;23(3):186-90.
10. Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. *Proc Soc Exp Biol Med* 1999;220:218–24.
11. Mukhtar H, Ahmad N. Green tea in chemoprevention of cancer. *Toxicol Sci* 1999;52(2 Suppl):111–7.
12. Mukhtar H, et al. Cancer Chemoprevention by Green Tea Components. *Adv Exp Med Biol.* 1994;354:123-34.
13. Nakachi K , et al. Influence of Drinking Green Tea on Breast Cancer Malignancy among Japanese Patients. *Jpn J Cancer Res.* Mar1998;89(3):254-61.
14. Sadzuka Y, et al. Modulation of Cancer Chemotherapy by Green Tea. *Clin Cancer Res.* Jan1998;4(1):153-56.

15. Stoner GD, Mukhtar H. Polyphenols as Cancer Chemopreventive Agents. *J Cell Biochem Supp.* 1995;22:169-80.
16. Suganuma M, Okabe S, Sueoka N, et al. Green tea and cancer chemoprevention. *Mutat Res* 1999;428:339-44.
17. Sugiyama T, Sadzuka Y. Enhancing Effects of Green Tea Components on the Antitumor Activity of Adriamycin Against M5076 Ovarian Sarcoma. *Cancer Lett.* Nov1998;133(1):19-26.
18. Weisberger JH, Rivenson A, Garr K, et al. Tea, or tea and milk, inhibit mammary gland and colon carcinogenesis in rats. *Cancer Lett* 1997;114:323-7.
19. Weisburger JH, Rivenson A, Aliaga C, Reinhardt J, Kelloff GJ, Boone CW, Steele VE, Balentine DA, Pittman B, Zang E. Effect of tea extracts, polyphenols, and epigallocatechin gallate on azoxymethane-induced colon cancer. *Proc Soc Exp Biol Med.* 1998 Jan;217(1):104-8.
20. Wu AH, Yu MC, Tseng CC, Hankin J, Pike MC. Green tea and risk of breast cancer in Asian Americans. *Int J Cancer.* Sep2003;106(4):574-9.
21. Yang CS, Lee MJ, Chen L, Yang GY. Polyphenols as inhibitors of carcinogenesis. *Environ Health Perspect* 1997;105(Suppl 4):971-6 [review].
22. Yu H, Oho T, Tagomori S, et al. Anticariogenic Effects of Green Tea. *Fukuoka Igaku Zasshi.* Apr1992;83(4):174-80.

E. Metabolic function

1. Elmetts CA, Singh D, Tubesing K, et al. Cutaneous Photoprotection from Ultraviolet Injury by Green Tea Polyphenols. *J Am Acad Dermatol.* Mar2001;44(3):425-432.
2. Goto K, Kanaya S, Ishigami T, Hara Y. The effects of tea catechins on fecal conditions of elderly residents in a long-term care facility. *J Nutr Sci Vitaminol* 1999;45:135-41.
3. Goto K, Kanaya S, Nishikawa T, et al. The influence of tea catechins on fecal flora of elderly residents in long-term care facilities. *Ann Long-Term Care* 1998;6:43-8.
4. Hamilton-Miller JM. Antimicrobial properties of tea (*Camellia sinensis* L.). *Antimicro Agents Chemother* 1995;39:2375-7.
5. Hodgson JM, Puddey IB, Burke V, et al. Effects on Blood Pressure of Drinking Green and Black Tea. *J Hypertens.* Apr1999;17(4):457-63.

6. Horiba N, Maekawa Y, Ito M, et al. A Pilot Study of Japanese Green Tea as a Medicament: Antibacterial and Bactericidal Effects. *J Endod.* Mar1991;17(3):122-4.
7. Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. *Endocrinology.* 2000 Mar;141(3):980-7.
8. Ooshima T, Minami T, Aono W, et al. Reduction of dental plaque deposition in humans by oolong tea extract. *Caries Res* 1994;28:146-9.
9. Otake S, Makimura M, Kuroki T, et al. Anticaries Effects of Polyphenolic Compounds from Japanese Green Tea. *Caries Res.* 1991;25(6):438-43.
10. Rasheed A, Haider M. Antibacterial Activity of *Camellia sinensis* Extracts Against Dental Caries. *Arch Pharm Res.* Jun1998;21(3):348-52.
11. Stammer G, et al. Green Tea Catechins (EGCG and EGC) Have Modulating Effects on the Activity of Doxorubicin in Drug-resistant Cell Lines. *Anticancer Drugs.* Mar1997;8(3):265-68.
12. Yan YS. Effect of Chinese Tea Extract on the Immune Function of Mice Bearing Tumor and Their Antitumor Activity. *Chung Hua Yu Fang I Hsueh Tsa Chih.* Jan 1992;26(1):5-7.
13. You SQ. Study on feasibility of Chinese green tea polyphenols (CTP) for preventing dental caries. *Chin J Stom* 1993;28:197-9.
14. Zeyuan D, Bingying T, Xiaolin L, et al. Effect of Green Tea and Black Tea on the Metabolisms of Mineral Elements in Old Rats. *Biol Trace Elem Res.* Oct 1998;65:75-86.
15. Zhu M, Gong Y, Ge G. Effects of green tea on growth inhibition and immune regulation of Lewis lung cancer in mice. *Chung Hua Yu Fang I Hsueh Tsa Chih.* 1997 Nov;31(6):325-9.

Bromelain

A. Tissue structure and function

1. Ahle NW, Hamlet MP. Enzymatic frostbite eschar debridement by bromelain. *Ann Emerg Med* 1987;16:1063-5.
2. Blonstein JL. Control of swelling in boxing injuries. *Practitioner.* 1960;185:78.
3. Blumenthal M, et al. *Herbal Medicine: Expanded Commission E Monographs.* Newton, MA: Integrative Medicine Communications;2000:33-35.

4. Craig RP. The quantitative evaluation of the use of oral proteolytic enzymes in the treatment of sprained ankles. *Injury*. 1975 May;6(4):313-6.
5. Fisher JD, Weeks RL, Curry WM, Hrinda ME, Rosen LL. Effects of an oral enzyme preparation, Chymoral, upon serum proteins associated with injury (acute phase reactants) in man. *J Med*. 1974;5(5):258-73.
6. France LH. Treatment of injuries with orally administered Varidase as compared to Chymoral and Tanderil. *Praxis*. 1968 May 14;57(19):683-5.
7. Gal P, Tecl F, Skotakova J, Mach V. Systemic enzyme therapy in the treatment of supracondylar fractures of the humerus in children. *Rozhl Chir*. 1998 Dec;77(12):574-6.
8. Hingorani K. Oral enzyme therapy in severe back pain. *Br J Clin Pract*. 1968 May 5;22(5):209-10.
9. Houck JC, Chang CM, Klein G. Isolation of an effective debriding agent from the stems of pineapple plants. *Int J Tissue React*. 1983;5(2):125-134.
10. Howat RCL, Lewis GD. The effect of bromelain therapy on episiotomy wounds—a double blind controlled clinical trial. *J Obstet Gynaecol Br Commonwealth* 1972;79:951–3.
11. Kelly G. Bromelain: A literature review and discussion of its therapeutic uses. *Alt Med Rev*. Vol 1. Nov1996;(4):120-23.
12. Levensen S. Supportive therapy in burn care. Debriding agents. *J Trauma* 1979;19(11 Suppl):8–30.
13. Lie KK, Larsen RD, Posch JL. Therapeutic value of oral proteolytic enzymes following hand surgery. *Arch Surg*. 1969 Jan;98(1):103-4.
14. Love JW. The effect of orally administered proteolytic enzymes on the postoperative course of periodontal surgery. *J Periodontol*. 1968 Nov;39(6):337-40.
15. Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. *Fortschr Med*. 1995;113:303-306.
16. Monograph: Bromelain. *Altern Med Rev*. Aug1998;3(4):302-5.
17. Neverov VA, Klimov AV. The pathogenetic basis for and clinical use of systemic enzyme therapy in traumatology and orthopedics. *Vestn Khir Im I I Grek*. 1999;158(1):41-4.

18. Rathgeber WF. The use of proteolytic enzymes (chymoral) in sporting injuries. *S Afr Med J*. 1971 Feb 13;45(7):181-3.
19. Sarkisov KR, Protasevich AI. On the use of proteolytic enzymes in the treatment of fractures of the mandible by extraoral supporting ligaments. *Vestn Khir Im I I Grek*. 1966 Apr;96(4):91-3.
20. Schwinger O. Results of oral enzyme therapy in wounds of muscles, tendons and bones after accidents. *Wien Med Wochenschr*. 1970 Sep 5;120(36):603-5.
21. Tassman GC, Zafran JN, Zayon GM. A double-blind crossover study of a plant proteolytic enzyme in oral surgery. *J Dent Med*. 1965;20:51-54.
22. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (*Ananas comosus*) and its clinical application. An update. *J Ethnopharmacol*. 1988;27:191-203.

B. Fluid Balance

1. Adamek J, Prausova J, Wald M. Enzyme therapy in the treatment of lymphedema in the arm after breast carcinoma surgery. *Rozhl Chir*. 1997 Apr;76(4):203-4.
2. Seltzer AP. Minimizing post-operative edema and ecchymoses by the use of an oral enzyme preparation (bromelain). *EENT Monthly* 1962;41:813-7.

C. Inflammation and Pain

1. Cohen A, Goldman J. Bromelains therapy in rheumatoid arthritis. *Pennsylvania Med J* 1964;67:27-30.
2. Cirelli MG. Treatment of inflammation and edema with bromelain. *Delaware Med J* 1962;34:159-67
3. Hayashi M. Pharmacological studies of Shikon and Tooki. (3) Effect of topical application of the ether extracts and Shiunko on inflammatory reactions. *Nippon Yakurigaku Zasshi* 1977;73:205-14 [in Japanese].
4. Izaka K, Yamada M, Kawano T, Suyama T. Gastrointestinal absorption and anti-inflammatory effect of bromelain. *Jpn J Pharmacol* 1972;22:519-34.
5. Klein G, et al. Reducing pain by oral enzyme therapy in rheumatic diseases. *Wien Med Wochenschr*. 1999;149(21-22):577-80.
6. Kumakura S, Tsurufuji S, Yamashita M. Effect of bromelain on kaolin-induced inflammation in rats. *Eur J Pharmacol*. 1988;150:295-301.

7. Nettis E, Napoli G, Ferrannini A, Tursi A. IgE-mediated allergy to bromelain. *Allergy* 2001;56:257-8.
8. Rovenska E, et al. Enzyme and combination therapy with cyclosporin A in the rat developing adjuvant arthritis. *Int J Tissue React.* 1999;21(4):105-11.
9. Ryan RE. A double-blind clinical evaluation of bromelains in the treatment of acute sinusitis. *Headache* 1967;7:13-7.
10. Schafer A, Adelman B. Plasma inhibition of platelet function and of arachidonic acid metabolism. *J Clin Invest* 1985;75:456-61.
11. Seligman B. Bromelain: an anti-inflammatory agent. *Angiology* 1962;13:508-10.
12. Seligman B. Oral bromelains as adjuncts in the treatment of acute thrombophlebitis. *Angiology* 1969;20:22-6.
13. Tassman GC, Zafran JN, Zayon GM. Evaluation of a plant proteolytic enzyme for the control of inflammation and pain. *J Dent Med.* 1964;19:73-77.
14. Walker AF, Bundy R, Hicks SM, Middleton RW. Bromelain reduces mild acute knee pain and improves well-being in a dose-dependent fashion in an open study of otherwise healthy adults. *Phytomedicine.* Dec2002;9(8):681-6.
15. Zatuchni GI, Colombi DJ. Bromelains therapy for the prevention of episiotomy pain. *Obstet Gynecol* 1967;29:275-8.

D. Metabolic Function

1. Batkin S, Taussig SJ, Szekerezes J. Antimetastatic effect of bromelain with or without its proteolytic and anticoagulant activity. *J Cancer Res Clin Oncol.* 1988;114:507-508.
2. Brakebusch M, Wintergerst U, Petropoulou T, Notheis G, Husfeld L, Belohradsky BH, et al. Bromelain is an Accelerator of Phagocytosis, Respiratory Burst and Killing of *Candida albicans* by Human Granulocytes and Monocytes. *Eur J Med Res.* May2001;6(5):193-200.
3. Desser L, Rehberger A, Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. *Cancer Biother.* 1994;9:253-263.
4. Desser L, et al. Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations. *Oncology.* Nov1993;50(6):403-7.

5. Eckert K, et al. Effects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patients. *Oncol Rep.* Nov1999;6(6):1191-9.
6. Engwerda CR, Andrew D, Murphy M, Mynott TL. Bromelain activates murine macrophages and natural killer cells in vitro. *Cell Immunol.* May2001;210(1):5-10.
7. Engwerda CR, Andrew D, Ladhams A, Mynott TL. Bromelain modulates T cell and B cell immune responses in vitro and in vivo. *Cell Immunol.* May2001;210(1):66-75.
8. Heinicke RM, et al. Effect of bromelain (Ananase) on human platelet aggregation. *Experientia.* Jul1972;28(7):844-5.
9. Knill-Jones RP, et al. Comparative double blind experience of a polyenzymatic preparation in chronic pancreatic insufficiency. *Acta Gastroenterol Belg.* Sep1973;36(9):489-504.
10. Knill-Jones RP, Pearce H, Batten J, et al. Comparative trial of Nutrizym in chronic pancreatic insufficiency. *Brit Med J.* 1970;4:21-24.
11. Lauer D, Muller R, Cott C, Otto A, Naumann M, Birkenmeier G. Modulation of growth factor binding properties of alpha2-macroglobulin by enzyme therapy. *Cancer Chemother Pharmacol.* Jul2001;47(Suppl):S4-9.
12. Metzigg C, et al. Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels. *In Vivo.* Jan1999;13(1):7-12.
13. Morita AH, et al. Chromatographic fractionation and characterization of the active platelet aggregation inhibitory factor from bromelain. *Arch Int Pharmacodyn Ther.* Jun1979;239(2):340-50.
14. Munzig E, Eckert K, Harrach T, et al. Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cells. *FEBS Lett.* 1995;351:215-218.
15. Schafer A, Adelman B. Plasmin inhibition of platelet function and of arachidonic acid metabolism. *J Clin Invest.* 1985;75:456-461.
16. Taussig SJ, Szekerczes J, Batkin S. Inhibition of tumor growth in vitro by bromelain, an extract of the pineapple plant (*Ananas comosus*). *Planta Med.* 1985;6:538-539.

Milk Thistle extract (seed)

A. Liver protection, alcohol abuse, glutathione regeneration

1. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Bocker RH, Beckurts KT, Lang W, Hunz M, Fuhr U. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. *Pharmacol Toxicol.* 2000 Jun;86(6):250-6.
2. Campos R, et al. Silybin Dihemisuccinate Protects Against Glutathione Depletion and Lipid Peroxidation Induced by Acetaminophen on Rat Liver. *Planta Medica.* 1989;55:417-19.
3. *Cardui mariae fructus (Milk Thistle fruit).* Commission E Monograph. Mar1986;Bundesanzeiger:no. 50.
4. Carrescia O, et al. Silymarin in the Prevention of Hepatic Damage by Psychopharmacologic Drugs. Experimental Premises and Clinical Evaluations. *Clin Ter.* 1980;95(2):157-64.
5. De Martiis M, Fontana M, Assogna G, D'Ottavi R, D'Ottavi O. Milk thistle (*Silybum marianum*) derivatives in the therapy of chronic hepatopathies. *Clin Ter.* 1980 Aug 15;94(3):283-315.
6. Deak G, Muzes G, Lang I, Niederland V, Nekam K, Gonzalez-Cabello R, Gergely P, Feher J. Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases. *Orv Hetil.* 1990 Jun 17;131(24):1291-2, 1295.
7. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer Cell Functions as an Explanation for the Hepatoprotective Properties of Silibinin. *Hepatology.* Apr1996;23(4):749-54.
8. Faulstich H, Jahn W, Wieland T. Silibinin inhibition of amatoxin uptake in the perfused rat liver. *Arzneim-Forsch Drug Res* 1980;30:452-4.
9. Feher J, Lang I, Deak G, et al. Free radicals in tissue damage in liver diseases and therapeutic approach. *Tokai J Exp Clin Med* 1986;11:121-34.
10. Ferenci P, Dragosics B, Dittrich H, et al. Randomized Controlled Trial of Silymarin Treatment in Patients with Cirrhosis of the Liver. *J Hepatol.* Jul1989;9(1):105-13.
11. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (*Silybum marianum*) for the therapy of liver disease. *Am J Gastroenterol.* 1998 Feb;93(2):139-43.
12. Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic actions of flavonolignans from *Silybum marianum* fruits. *Planta Medica* 1984;50:248-50.
13. Kiesewetter E, Leodolter I, Thaler H. Results of two double-blind studies on the effect of silymarine in chronic hepatitis. *Leber Magen Darm.* 1977 Oct;7(5):318-23.

14. Leng-Peschlow E. Alcohol-related liver diseases-use of Legalon®. *Z Klin Med* 1994;2:22-7.
15. Margaroli P, Rossi M, Arcabasso GD, Cosini I, Malacrida C. Evaluation of the therapeutic effects of silymarin. *Clin Ter.* 1980 Dec 31;95(6):663-72.
16. Morelli I. Constituents of *Silybum marianum* and their therapeutic use. *Boll Chim Farm.* 1978 May;117(5):258-67.
17. Pares A, Planes R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. *J Hepatol* 1998;28:615-21.
18. Realini S, Gonvers JJ, Hofstetter JR. Clinical investigation of silymarin in chronic liver diseases. *Schweiz Rundsch Med Prax.* 1975 May 13;64(19):595-8.
19. Reutter FW, Haase W. Clinical experience with silymarin in the treatment of chronic liver disease. *Schweiz Rundsch Med Prax.* 1975 Sep 9;64(36):1145-51.
20. Rue YC. Advances in Pharmacological Studies of Silymarin. *Mem Inst Oswaldo Cruz.* 1991;86(Suppl 2):79-85.
21. Saliou C, Rihn B, Cillard J, Okamoto T, Packer L. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. *FEBS Lett.* 1998 Nov 27;440(1-2):8-12.
22. Salmi H, Sama S. Effect of Silymarin on Chemical, Functional, and Morphological Alterations of the Liver. A Double-blind Controlled Study. *Scand J Gastroent.* 1982;17:517-21.
23. Sawaryn T, Szymonski K, Machalska M. Silymarin in the treatment of chronic hepatitis. *Przegl Epidemiol.* 1977;31(4):445-50.
24. Schopen RD, et al. Therapy of Hepatoses. Therapeutic Use of Silymarin. *Med Welt.* 1969;21:691-98.
25. Tuchweber B, Sieck R, Trost W. Prevention by silibinin of phalloidin induced hepatotoxicity. *Toxicol Appl Pharmacol* 1979;51:265-75.
26. Valenzuela A, et al. Selectivity of Silymarin on the Increase of the Glutathione Content in Different Tissues of the Rat. *Planta Medica.* 1989;55:1550-52.
27. Varga M, et al. Ethanol Elimination in Man Under Influence of Hepatoprotective Silibinin. *Blutalkohol.* Nov1991;28(6):405-08.

28. Velussi M, Cernogoi AM, De Monte A, et al. Long-term (12 months) treatment with an antioxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. *J Hepatology* 1997;26:871–9.
29. Wichtl M in Bissett NA, ed. *Herbal Drugs and Phytopharmaceuticals*. Stuttgart: Scientific Press; 1994:121-23.

B. Liver structure and function

1. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol* 1989;9:105–13.
2. Sonnenbichler J, Zetl I. Stimulating influence of a flavanolignan derivative on proliferation, RNA synthesis and protein synthesis in liver cells. In *Assessment and Management of Hepatobiliary Disease*, ed. L Okolicsanyi, G Csomos, G Crepaldi. Berlin: Springer-Verlag, 1987, 265–72.

C. Bile, cholesterol and fat metabolism

1. Edwards J, Grange LL, Wang M, et al. Fetoprotectivity of the Flavanolignan Compound Siliphos Against Ethanol-induced Toxicity. *Phytother Res*. Nov2000;14(7):517-21.
2. Krecman V, Skottova N, Walterova D, et al. Silymarin Inhibits the Development of Diet-induced Hypercholesterolemia in Rats. *Planta Med*. Mar1998;64(2):138-42.
3. Nassuato G, Iemmolo RM, Strazzabosco M, et al. Effect of silibinin on biliary lipid composition. Experimental and clinical study. *J Hepatol* 1991;12:290–5.
4. Skottova N, Krecman V, Walterova D, et al. Effect of Silymarin on Serum Cholesterol Levels in Rats. *Acta Univ Palacki Olomuc Fac Med*. 1998;141:87-9.
5. Skottova N, Krecman V. Silymarin as a Potential Hypocholesterolaemic Drug. *Physiol Res*. 1998;47(1):1-7.

D. Antioxidation/detoxification

1. Allain H, Schück S, Lebreton S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. *Dementia Geriatr Cogn Disorders* 1999;10:181–5.
2. Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. *Med Klin*. 1999 Oct 15;94 Suppl 3:84-9.

3. Desplaces A, et al. The Effects of Silymarin on Experimental Phalloidine Poisoning. *Arzneim-Forsch/Drug Res.* 1975;25:89-96.
4. Palasciano G, Portinascasa P, Palmieri V, et al. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long-term treatment with psychotropic drugs. *Curr Ther Res* 1994;S5:S37-45.
5. Par A, Roth E, Rumi G Jr, Kovacs Z, Nemes J, Mozsik G. Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C. *Orv Hetil.* 2000 Jul 23;141(30):1655-9.
6. Stickel F, Egerer G, Seitz HK. Hepatotoxicity of botanicals. *Public Health Nutr.* 2000 Jun;3(2):113-24.
7. Valenzuela A, et al. Silymarin Protection Against Hepatic Lipid Peroxidation Induced by Acute Ethanol Intoxication in the Rat. *Biochem Pharm.* 1985;34:2209-12.
8. Vogel G, et al. Protection by Silibinin Against Amanita Phalloides Intoxication in Beagles. *Toxicol Appl Pharm.* 1984;73:355-62.

E. Oxygen depletion

1. Zhao J, Sharma Y, Agarwal R. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion. *Mol Carcinog.* 1999 Dec;26(4):321-33.

F. Fibrotic tissue

1. Schuppan D, Strösser W, Burkard G, Walosek G. Legalon® lessens fibrosing activity in patients with chronic liver diseases. *Zeits Allgemeinmed* 1998;74:577-84.

G. Acetaminophen poisoning

1. Shear NH, Malkiewicz IM, Klein D, et al. Acetaminophen-induced Toxicity to Human Epidermoid Cell Line A431 and Hepatoblastoma Cell Line Hep G2, In Vitro, is Diminished by Silymarin. *Skin Pharmacol.* 1995;8(6):279-91.

H. Inflammation

1. Fiebrich F, et al. Silymarin, an Inhibitor of Prostaglandin Synthetase. *Experimenta.* 1979;35:150-52.

2. Gupta OP, Sing S, Bani S, et al. Anti-inflammatory and Anti-arthritic Activities of Silymarin Acting Through Inhibition of 5-lipoxygenase. *Phytomedicine*. Mar2000;7(1):21-4.
3. Manna SK, Mukhopadhyay A, Van NT, et al. Silymarin Suppresses TNF-induced Activation of NF-kappa B, c-Jun N-terminal Kinase, and Apoptosis. *J Immunol*. Dec1999;163(12):6800-9.

Capsicum frutescens

A. Metabolic function, fat metabolism and Circulation

1. Bortolotti M, Coccia G, Grossi G. Red pepper and functional dyspepsia. *N Engl J Med* 2002;346:947-8 [letter].
2. Chaiyata P, Puttadechakum S, Komindr S. Effect of chili pepper (*Capsicum frutescens*) ingestion on plasma glucose response and metabolic rate in Thai women. *J Med Assoc Thai*. Sep2003;86(9):854-60.
3. Guengerich FP. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. *Am J Clin Nutr*. 1995 Mar;61(3 Suppl):651S-658S.
4. Visudhiphan S, Poolsuppasit S, Piboonnukarintr O, et al. The Relationship Between High Fibrinolytic Activity and Daily Capsicum Ingestion in Thais. *Am J Clin Nutr*. Jun1982;35(6):1452-8.
5. Yoshioka M, St-Pierre S, Drapeau V, et al. Effects of red pepper on appetite and energy intake. *Br J Nutr* 1999;82:115-23.
6. Yoshioka M, St-Pierre S, Suzuki M, Tremblay A. Effects of red pepper added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization in Japanese women. *Br J Nutr* 1998;80:503-10.

B. Obesity, fat metabolism, carbohydrate metabolism

1. Egger G, Cameron-Smith D, Stanton R. The effectiveness of popular, non-prescription weight loss supplements. *Med J Aust*. 1999 Dec 6-20;171(11-12):604-8.
2. Lim K, Yoshioka M, Kikuzato S, Kiyonaga A, Tanaka H, Shindo M, Suzuki M. Dietary red pepper ingestion increases carbohydrate oxidation at rest and during exercise in runners. *Med Sci Sports Exerc*. 1997 Mar;29(3):355-61.
3. Yoshioka M, St-Pierre S, Drapeau V, Dionne I, Doucet E, Suzuki M, Tremblay A. Effects of red pepper on appetite and energy intake. *Br J Nutr*. 1999 Aug;82(2):115-23.

C. Immune system

1. Yu R, et al. Modulation of Select Immune Responses by Dietary Capsaicin. *Int J Vitam Nutr Res.*1998; 68(2):114-19.